Huons Q1 2026: Operating Loss but Net Profit Positive, New Dividend Policy and Merger Announced

Q1 2026 consolidated sales KRW 141.8bn, operating loss KRW 0.65bn, net profit attributable to parent KRW 0.34bn (swing to loss vs full-year operating profit of KRW 45.6bn in 2025).
Established mid-term dividend policy (2026-2028): quarterly dividend KRW 200/share, annual KRW 800/share, with annual increase target of 5-30% (shareholder return enhancement).
After reporting period, on April 23, 2026, signed absorption merger agreement with subsidiary Huons Life Science (merger expected on June 23).
Major litigation: Bristol-Myers Squibb apixaban patent damages case – partially lost in first instance; both parties appealed.
Subsidiary PanGen early redeemed 3rd convertible bonds of KRW 1.0bn (April 20, 2026).
Provided guarantees to related parties: KRW 34.02bn (Huons Life Science, Huons N, BioRoget).
Consolidated R&D expenses KRW 11.74bn (8.28% of sales), up from 6.73% in prior full year.
Total assets KRW 661.3bn, total liabilities KRW 253.3bn, total equity KRW 408.0bn.

ADVERTISEMENT (250px+)